TABLE 4.
Risk factors for COVID-19 after mRNA vaccination
| Odds ratio | 95% CI | p value | |
|---|---|---|---|
| Univariatea | |||
| Time posttransplant (per 1 month increase) | 0.971 | 0.946–0.996 | .026 |
| Age (per 1 year increase) | 0.977 | 0.947–1.008 | .144 |
| Chronic glomerulonephritis (ref. = other causes) | 1.757 | 0.858–3.594 | .123 |
| Cardiovascular disease (ref. = none) | 0.485 | 0.230–1.022 | .057 |
| Tacrolimus (ref. = cyclosporine or sirolimus)b | 6.791 | 0.897–51.4 | .064 |
| Estimated GFR (per 1 ml/min increase) | 0.986 | 0.968–1.005 | .150 |
| Multivariate | |||
| Time posttransplant (per 1 month increase) | 0.975 | 0.963–0.987 | <.001 |
| Cardiovascular disease (ref. = none) | 0.441 | 0.198–0.981 | .045 |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; GFR, glomerular filtration rate.
a
Variables with p-value ≤ .2 are shown.
b
Both tacrolimus level (odds ratio, 1.036, 95% CI, 0.872–1.230 per 1 ng/ml increase, p = .688) and mycophenolate mofetil dose (odds ratio, 1.000, 95% CI, 1.000–1.001 per 1 mg/day increase, p = .361) did not reach significance.